Results 11 to 20 of about 2,139 (156)

Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230 [PDF]

Frontiers in Immunology
BackgroundBullous pemphigoid (BP) and mucous membrane pemphigoid (MMP) are rare autoimmune blistering disorders characterized by autoantibodies (autoAbs) targeting dermo-epidermal junction components such as BP180 and BP230.
Feliciana Mariotti, Anna Pira, Naomi De Luca, Anna Rita Giampetruzzi, Filomena Russo, Amilcare Cerri, Giulia Gasparini, Giulia Gasparini, Emanuele Cozzani, Emanuele Cozzani, Angelo V. Marzano, Angelo V. Marzano, Emiliano Antiga, Marzia Caproni, Pietro Quaglino, Marco Carrozzo, Biagio Didona, Giovanni Di Zenzo   +17 more
doaj   +8 more sources

Analysis of the autoimmune response against BP180 and BP230 in ethnic Poles with neurodegenerative disorders and bullous pemphigoid [PDF]

Central European Journal of Immunology, 2017
Recent studies postulated the association between bullous pemphigoid (BP) and neurodegenerative disorders (ND). The autoantibodies to BP180 and/or BP230 may be present not only in BP, but also in ND as neuronal isoforms of these proteins are identified ...
Justyna Gornowicz-Porowska, Agnieszka Seraszek-Jaros, Monika Bowszyc-Dmochowska, Elżbieta Kaczmarek, Paweł Pietkiewicz, Paweł Bartkiewicz, Marian Dmochowski   +6 more
doaj   +2 more sources

High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid

Frontiers in Medicine, 2018
Bullous pemphigoid (BP) presenting with erythema plaques and tense blisters is the most frequent autoimmune bullous disease. Immunologically, BP is characterized by the presence of circulating anti-epidermal basement membrane zone (BMZ) antibodies.
Hiroshi Koga, Kwesi Teye, Norito Ishii, Chika Ohata, Takekuni Nakama   +4 more
doaj   +2 more sources

Profiling the serum cytokine B cell activating factor (BAFF),proliferation inducing ligand (APRIL), and BP180, BP230 antibodies in bullous pemphigoid patients before and after treatment: a prospective case-control study

Clinical Immunology Communications
Background: Bullous pemphigoid is a subepidermal autoimmune blistering disease caused by auto-antibodies directed against specific components of the basement membrane molecules.
Shadab Seraji, Kamran Balighi, Amir Hooshang Ehsani, Ala Ehsani, Hamidreza Mahmoudi, Maryam Daneshpazhooh, Pedram Noormohammadpour, Saman Al Zahawi, Zeinab Aryanian, Parvaneh Hatami   +9 more
doaj   +2 more sources

Current approaches to the diagnosis of autoimmune bullous dermatoses

Vestnik Dermatologii i Venerologii, 2021
A modern review of highly effective methods for the diagnosis of autoimmune bullous dermatoses are presented. The specificity of the production of autoantibodies underlying bullous dermatoses are described.
Marianna B. Drozhdina, Varvara A. Bobro, Yuliana A. Sennikova   +2 more
doaj   +1 more source

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

Frontiers in Medicine, 2022
BackgroundBullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal ...
Francesco Moro, Francesco Moro, Feliciana Mariotti, Anna Pira, Naomi De Luca, Biagio Didona, Gianluca Pagnanelli, Giovanni Di Zenzo   +7 more
doaj   +1 more source

Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study

Frontiers in Medicine, 2022
Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have been described following vaccinations against tetanus, poliomyelitis, diphtheria, influenza,
Carlo Alberto Maronese, Carlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, Chiara Moltrasio, Giovanni Genovese, Giovanni Genovese, Pamela Vezzoli, Paolo Sena, Giulia Previtali, Emanuele Cozzani, Giulia Gasparini, Aurora Parodi, Laura Atzori, Emiliano Antiga, Roberto Maglie, Francesco Moro, Elena Biancamaria Mariotti, Alberto Corrà, Sabatino Pallotta, Biagio Didona, Angelo Valerio Marzano, Angelo Valerio Marzano, Giovanni Di Zenzo   +23 more
doaj   +1 more source

Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid

Dermatologic Therapy, 2022
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230.
Camilla Vassallo, Anita Somenzi, Mara De Amici, Stefania Barruscotti, Valeria Brazzelli   +4 more
doaj   +1 more source

Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review

Frontiers in Medicine, 2021
Bullous pemphigoid (BP) is the most common type of autoimmune bullous disease and is characterized by the presence of circulating anti-BP180 and/or anti-BP230 autoantibodies.
Xinyi Chen, Wenlin Zhao, Hongzhong Jin, Li Li   +3 more
doaj   +1 more source

Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders

Frontiers in Immunology, 2021
Bullous pemphigoid (BP) is a prototypic autoimmune disorder of the elderly, characterized by serum IgG autoantibodies, namely anti-BP180 and anti-BP230, directed against components of the basal membrane zone that lead to sub-epidermal loss of adhesion ...
Dario Didona, Luca Scarsella, Milad Fehresti, Farzan Solimani, Farzan Solimani, Hazem A. Juratli, Manuel Göbel, Stefan Mühlenbein, Lily Holiangu, Josquin Pieper, Vera Korff, Thomas Schmidt, Cassian Sitaru, Rüdiger Eming, Michael Hertl, Robert Pollmann   +15 more
doaj   +1 more source